Chugai deal with Japanese govt on antibody cocktail for COVID-19

10 May 2021

Chugai Pharmaceutical (TYO: 4519) has reached agreement with the Japanese government regarding the antibody cocktail casirivimab and imdevimab (formerly known as REGN-COV2), which is being investigated as a potential treatment for COVID-19.

Under this accord, the Japanese government will secure the antibody cocktail for the year 2021 for domestic supply, if it is approved by the regulatory authority in Japan.

The antibody cocktail combining two virus-neutralizing antibodies, casirivimab and imdevimab, was developed by USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) for the potential treatment and prevention of COVID-19.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK